Notoriously hard to treat, pancreatic and colorectal cancers each have high recurrence rates in the years following treatment ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

According to them, the vaccine can safely and effectively train the immune system to recognise and fight cancer-driving ...

A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...

The "off-the-shelf" vaccine has also shown promising results for pancreatic cancer. Since the U.S. Preventive Services Task ...

A new off-the-shelf peptide vaccine has proven effective against pancreatic and colorectal cancer, reducing the chances of ...